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Enhancement in Xerostomia Patient Salivary Lubrication 
using a Mucoadhesive 
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Oral lubrication mediated by salivary conditioning films (SCFs) containing 
mucins and proteins with strong water retainability can get impaired due to 
disease such as xerostomia, that is, a subjective dry mouth feel associated with 
the changed salivary composition and low salivary flow rate. Aberrant SCFs in 
xerostomia patient causes difficulties in speech, mastication, dental erosion 
while the prescribed artificial saliva are inadequate to solve the complications 
on a lasting basis. With the growing aging population, it is urgently need to 
propose a new strategy to restore oral lubrication. Existing saliva substitutes 
often overwhelm the aberrant SCFs, generating inadequate relief. Here we 
demonstrated that the function of aberrant salivary SCFs in patient with 
Sjögren syndrome can be boosted through mucin recruitment by a simple 
mucoahesive, chitosan-catechol (Chi-C). Chi-C with different conjugation 
degrees (Chi-C7.6%, Chi-C14.5%,  Chi-C22.4%) were obtained by carbodiimide 
chemistry, which induced a layered structure composed of a rigid bottom and 
a soft secondary SCF (S-SCF) after reflow of saliva. The higher conjugation 
degree of Chi-C generates a higher glycosylated S-SCF by mucin recruitment 
and a lower friction in vitro. The  layered S-SCF extends the “Relief Period” for 
Sjögren patient saliva over 7-fold, measured on an ex vivo tongue-enamel 
friction system. Besides lubrication, Chi-C-treated S-SCF reduces dental erosion 
depths from 125 to 70μm. Chi-C shows antimicrobial activity against 
Streptococcus mutans. This research provides a new key insight in restoring the 
functionality of conditioning film at articulating tissues in living systems. 
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Reduced saliva secretion and altered salivary composition are associated with 
xerostomia, that is, a subjective dry mouth feel, which seriously decreases the 
quality of patient life. Sjögren’s syndrome 1,2; head neck radiation therapy 3 
and use of medication 4 causes xerostomia (dry mouth). Glycoproteins i.e. 
mucins 5 in SCFs, retain water and yield unmatchable hydration lubrication on 
oral surface 6. However, the aberrant SCFs of xerostomia patient with limited 
mucins attributed to the changed salivary composition and low salivary flow 
rate yield poor lubrication associated with dental erosion and dental caries 7. 
To mellow the symptoms, xerostomia patients use saliva substitutes, which 
contains either food-grade thickeners extracted from animal and plant sources 
or lubricant molecules like porcine gastric mucins (PGM), often masking the 
native SCFs. A Cochran collaboration 8, in which 1597 patients were included, 
concluded that topical delivery of saliva substitutes is ineffective in relieving 
dry mouth symptoms, which is also confirmed by Vinke et al. with the help of a 
tongue-enamel friction model 9,10 
In an actual dry oral cavity with limited saliva, endogenous glycoproteins, 
including mucins, are available and could potentially be use as a part of 
treatment instead of being disregarded. Thus, an alternate strategy could be 
where instead of overwhelming the dry oral cavity with exogenous molecules, 
we work together and make mucins part of the solution. Intrigued by the fact 
that cationic polyelectrolytes 11 can improve the mechanical strength of 
polysaccharide multilayers, we tested their ability to act as an additive to 
improve oral lubrication by enhancing the SCFs. Chitosan12,13, is a nature-
derived cationic mucoadhesive with strong electrostatic interactions and a 
large amount of hydrogen bonding14, especially after modified with catechol  
(Chi-C), which endows it water solubility at neutral pH12.  Chi-C  shows a high 
affinity to glycoprotein whose oxidized derivative can bioconjugate with 
amines and cysteine residues of protein or glycoprotein through Michael 
addition or Schiff bases formation 15–18, while its potential to stabilize SCF has 
never been investigated. We hypothesized that Chi-C will bind to and absorbs 











glycoproteins from saliva through electrostatic attraction and chemical binding 
to boost SCFs, which can enhance oral lubrication and resist dental erosion. 
Here we tested the above hypothesis based on Chi-C with increasing 
conjugation degree (Chi-C7.6%, Chi-C14.5%,  Chi-C22.4%). The kinetics of the SCF 
formation, the modification with Chi-C, and the formation of secondary SCF (S-
SCF) during reflow of saliva were monitored by quartz crystal microbalance 
with dissipation (QCM-D).  The composition alteration in SCFs was determined 
by X-ray photoelectron spectroscopy (XPS). Lubrication properties of S-SCF 
with Chi-C treatment at the nanoscale were investigated by colloidal probe 
atomic force microscopy (AFM), and saliva from patient with Sjögren’s by Chi-C 
treatment was evaluated on an ex vivo tongue-enamel friction system10 at 
macro-scale. The antimicrobial efficacy of Chi-C and the ability of Chi-C-treated 
S-SCF to resist dental erosion were also tested. 
2. Materials and Methods  
2.1. Chi-C synthesis, monitoring of adsorption SCF with Chi-C treatment and 
their changes of composition and lubrication at nanoscale 
Chi-C was synthesized using carbodiimide chemistry12-13 and details are present 
in the SI. A standard protocol was followed to collect and prepare stimulated 
whole saliva (SWS) from both healthy and patient volunteers. SWS from both 4 
healthy (HS) and 4 patients (PS) suffering from  Sjögren’s syndrome, were 
collected for tongue-enamel friction measurement. All saliva collection and use 
were performed under the approval of the Medical Ethics Review Board of the 
University Medical Center Groningen (approval numbers M17.217043, 
M09.069162, M17.2157256, and UMCG IRB #2008109). QCM-D device model 
Q-sense E4 (Q-sense, Gothenburg, Sweden) was used to study the structural 
softness and formation kinetics of SCFs in vitro with or without Chi-C 
treatment. Briefly, saliva induced to the cleaned QCM-D sensor with 50µL/min, 
25°C for 2h, corresponding with a shear rate of 3 s−1 represents a low oral 
salivary flow rate and followed by perfused with buffer or 0.05% w/v of Chi-C 
for 2 min and finally induced with another 2 h of saliva flow to form a 
secondary SCF (S-SCF). In between each step, the chamber was perfused with 




crystal surface. The crystals coated by a S-SCF with or without Chi-C treatment 
were taken out from QCM-D for surface composition analysis by X-ray 
photoelectron spectroscopy (Details in SI) and nano-lubricity evaluation by 
colloidal probe atomic force microscopy(Details in SI). 
2.2. Tongue-enamel friction system10 
The friction measurements at macroscale were performed in reciprocating 
sliding between the tongue and enamel using the same protocol as Vinke et 
al.10 with a universal mechanical tester (UMT-3, CETR Inc., USA) under a normal 
force of 0.25 N at a sliding velocity of  4 mm/s and distance of 20 mm. The 
ratio of measured friction force and applied normal force was taken as the 
coefficient of friction (COF). 
Firstly the enamel was slid against the tongue for 10 cycles to obtain dry 
baseline and mimic dry mouth10. Then, a drop of 20 µL of SWS from healthy 
controls or Sjögren’s patients was placed at the tongue-enamel interface and 
rubbed 4 cycles to spread out forming the initial SCF, followed by another 20µL 
of buffer or Chi-C22.4% and 4 cycles of rubbing (step 3), finally  another 20µL of 
healthy or patient SWS was add forming the S-SCFs and the sliding was 
continued. The ratio between COF measured in dry baseline and S-SCFs was 
designated as ‘Relief’ using equation 1. The duration for which the COF 
remained low was designated as ‘Relief Period’.     
Relief=COFdry / COFwet                     (1) 
2.3. Dental erosion protection and antimicrobial and biocompatibility 
Dental erosion was tested using an established protocol 21,22  on the bovine 
incisors, detailed protocol is presented in the supplementary information. The 
antimicrobial efficacy of Chi-C was tested on Streptococcus mutans, and safety 
of Chi-C use was tested using the mouse fibroblastic cell line (L929) with the 
help of XTT assay 23 and microscopic examination of the cells. The protocols are 
described in detail in the supplementary information. 
2.4. Statistical analysis  
All data are expressed as means ± SD. Differences between groups determined 











3. Results  
3.1. Preparation and characterization of Chi-C 
Chi-C with three conjugation degrees was successfully and respectively called 
Chi-C7.6%, Chi-C14.5%, and Chi-C22.4%. H-NMR and UV-Vis spectrophotometry 
helped prove conjugation (Figure S1) and calculation of the conjugation degree, 
results are described in detail in the supplementary information.  
3.2. In vitro modification of SCF due to Chi-C 
After 2 hours of salivary flow on the bare sensor, a large amount of salivary 
protein adsorption on the sensor surfaces takes place as shown by a large 
frequency shift (∆f3) of -70±10 Hz and a dissipation (∆D3) greater than 10
-5 
(Figure 1). Exposure of SCF to buffer (Figure 1a) yielded a small change in ∆f3 
and ∆D3, while exposure to Chi-C solutions (0.5 mg/ml) with 3 conjugation 
degrees, a significant decrease in ∆D3/∆f3 (Figures 1b-d) (hollow bars in Figure 
1f) was observed, suggesting a Chi-C induced compaction of the SCF with 
hydrogen bonding, electrostatic attraction and covalent bonding irrespective 
of the conjugation degree. To mimic the oral situation saliva was reintroduced 
in the QCM-D, which caused renewed adsorption of salivary proteins and the 
formation of secondary SCF (S-SCF) (Figures 1a-d). The higher conjugate 
degree of Chi-C14.5% (-160±15 Hz) and Chi-C22.4% (-170±8.6 Hz) led to larger 
frequency shift ∆f3 and higher ∆D3/∆f3 as compare to Chi-C7.6% (-130±10Hz) and 
buffer (-75±10Hz) exposure.  
3.3. In vitro changes in topography, lubrication, and composition of S-SCFs 
induced by Chi-C 
Salivary protein adsorption was also evident from the morphology of the S-
SCFs as investigated by AFM and shown in Figure 2a. Bare sensor shows a 
smooth surface, but uneven, globular structures appeared after the adsorption 
of salivary protein with heights of about 23±4nm. Numerous similar structures 
were observed at 30±7nm in S-SCF with Chi-C7.6%, 38±5nm in S-SCF with Chi-
C14.5% and 37±7nm in S-SCF with Chi-C22.4%. Mucins in the SCFs are believed to 
be absorbed in the form of loops and trains on the surface5 and higher globular 




which could be caused by a large amount of mucin recruitment on the top 
layer.  
 
Figure 1. Kinetics of SCF formation, Chi-C adsorption to SCF, and renewed exposure to 
saliva to get S-SCF using the quartz crystal microbalance with dissipation (QCMD). The 
mass adsorption was quantified by frequency shift and structural softness by 
calculating the ratio between dissipation and frequency shift. SCF treated with buffer 
(a), Chi-C7.6%  (b), with Chi-C14.5% (c) and Chi-C22.4% (d), respectively. (e) Frequency shift 
after renewed exposure to saliva and (f) structural softness of SCF with and without 
(buffer) Chi-C adsorption and renewed exposure to saliva. Error bar represents the 
standard deviation over three independent measurements.
 *
Statistically significant 
(p<0.05, two tailed student t-test) differences in softness and frequency compared to 
control film. 
# 
Significant differences in frequency or softness of S-SCF with Chi-C22.4% 
treatment compared to S-SCF with Chi-C7.6% treatment.
& 
Significant difference in 












Figure 2. S-SCF change in composition, measured using XPS, in topography and nano-
friction, measured by AFM and colloidal probe AFM. (a) Surface topography of bare 
Au-coated crystal, S-SCF treated with buffer, Chi-C7.6%, Chi-C14.5%, and Chi-C22.4%, 
respectively. (B) The amount of glycoprotein (%O) in S-SCF with buffer or different 
conjugate degree Chi-C treatment were obtained from a decomposition of O1s 
photoelectron peak in XPS. (c) Friction force versus applied load curves of bare QCM-D 
crystal, S-SCF treated with buffer or Chi-C, respectively. (d) COF of each S-SCF 
calculated by slope of the linear fitting. (e) Correlation between structural softness of 
S-SCF and COF, and the higher structural softness of S-SCF the lower COF was achieved. 
*Statistically significant differences (p<0.05) in the content of glycoprotein in S-SCF 
with Chi-C treatment respect to S-SCF with buffer treatment in (b), or COF between S-
SCF and bare crystal in (d). 
#
Statistically significant (p<0.05) difference in COF of S-SCF 
treated with Chi-C respect to treated with buffer. 
& 
Significant difference in COF 
between S-SCF with Chi-C22.4.% and Chi-C7.6% treatment respectively. 
Mucin recruitment is also confirmed by the increased glycosylation of the S-
SCFs with different Chi-C treatments (Figure 2b, S3, and Table 1, S1) measured 
using X-ray photoelectron spectroscopy. The result from Table 1 showed a 
different relative content of C, O, N. The C1s spectra of each surface could be 
deconvoluted into four different peaks: C-(C,H), C-N/C-O, and O-C-O/ O=C-O, 






S-SCF with Chi-C7.6% 
S-SCF with Chi-C14.5% 






as shown in Figure S3 and Table 1, suggesting different proteins were present 
on the surface. In S-SCF with Chi-C treatment, the relative content of C-C was 
slightly decreased while the C-N was increased in Table 1, which may attribute 
to the protein or glycoprotein recruited to the surface. As for the O1s spectra, it 
could be deconvoluted into two components: O=C-N and H-O-C considered as 
the O from protein and glycol group respectively. The relative contents of 
glycoprotein could be calculated by the integral of O1s at 532.7ev in Figure 2b 
and S2. The higher amount of O1s at 532.7ev 
20 i.e. about 9.88±1.6 and 9.35±1.3 
was achieved in SCF with Chi-C22.4% and Chi-C14.5%  modification respectively 
while only 5.39±2.25 and 7.04±2.6 was detected in SCF with buffer and Chi-C7.6% 
treatment respectively. This indicates that Chi-C can recruit glycoprotein on 
the SCF surface to increase the glycosylation, which is in agreement with the 
higher ∆D3/∆f3 measured by QCM-D. The QCM-D crystals with S-SCFs were 
mounted under the colloidal probe AFM for lubrication evaluation. On the bare 
gold (Au), Ff increased linearly with Fn, corresponding to a COF of 0.25±0.03 
(Figure 2c,d), which is consistent with the literature 24 where give a COF of 0.28 
between silica ball and QCM crystal. Formation of S-SCF with an intermediate 
exposure to buffer decreased the COF to 0.132±0.021 (Figure 2c,d). S-SCFs 
with intermediate exposure to Chi-C further decreased the COF to 
0.053±0.0052 with Chi-C7.6%, 0.051±0.0053 with Chi-C14.5%, and the extremely 
low COF was observed on S-SCFs with intermediate exposure to Chi-C22.4% 
about 0.047±0.0031. A clear correlation between the increasing structural 
softness and decreasing COF was obtained (Figure 2e). A plateau with respect 
to COF was achieved with Chi-C22.4% indicating that any further increase in the 
conjugation degree will probably not provide any further decrease in friction. 
The lowest COF was detected for S-SCF with Chi-C22.4% treatment, 
corresponding to the highest mass adsorption (Figure 1e), highest structural 
softness (Figure 1f), and highest glycosylation (Figure 2d). Since Chi-C caused 
rigidification (Figure 1f) of the lower layer (SCF) irrespective of the Chi-C 
conjugation degree, the decrease in friction can be mainly attributed to 











Table 1. Surfaces chemical bonding of S-SCF with or without (PBS) Chi-C treatment. 
Samples C1s BE and relative area (%)  O1s BE and relative area 
(%) C-C C-N O-C-O O-C=O  N-C=O H-O-C 
S-SCF-PBS 61.6 22.4 12.3 3.7  66.3 33.7 
S-SCF-Chi-C7.6% 52.2 30.2 14.9 2.7  49.9 50.1 
S-SCF-Chi-C14.5% 56.3 27.5 13.8 2.4  48.7 51.3 
S-SCF-Chi-C22.4% 58.5 30.5 7.7 3.3  43.3 56.7 
 
3.4. Translation of an in-vitro observation to the ex-vivo stage and for patient 
saliva 
Chi-C22.4%  was chosen to explore its potential lubrication enhancement efficacy 
with patient saliva suffering from Sjögren’s syndrome (an aetiology of 
xerostomia) on the tongue-enamel system9,10 using real biological tissue, which 
can give the information of ‘Relief’ and ‘Relief period’. Consistent with the 
observations in previous studies, a COFdry of around  2.5 was observed (Figure 
3). A sharp drop in COF was observed after formation of initial SCF with an 
introduction of 20 µL saliva (called COFwet). From Figures 3c and 3d (black up 
arrow), a slight increase in COFwet is clearly visible both for patient saliva (PS) 
and healthy saliva (HS) immediately after the interaction of Chi-C22.4% with the 
SCF indicating a very strong stabilization and compaction due to the hydrogen 
bond, irreversible covalent formation, electrostatic attraction (Figure 1f). Upon 
re-exposure to 20µl saliva, the COF again decreases, which is caused by the 
formation of a softer S-SCF by recruiting salivary glycoproteins (Figure 2c). 
Although no significant difference was found in the relief between PS and HS 
after treatment with either buffer (5.2±1.2 folds and 4.9±1.2 folds respectively) 
or Chi-C22.4% (5.1±1.1 folds and 5.0±1.3 folds respectively) the relief period 
(Figure 3f ) of S-SCFs with Chi-C22.4% treatment were drastically elongated 
extended both for PS (25±4.8 min) and HS (36±3.3min) compared to buffer 
treatment in PS (3.3±1.3min) and HS (7.2±0.3min) respectively. The longer 
relief period is attributed to Chi-C22.4% which stabilized the SCF and recruited 
salivary glycoproteins to form a very soft S-SCF (Figure 1f, 3g). The significantly 
lower relief period was observed for PS compare to HS after treated with Chi-




molecules 25–27 compared to HS, which was confirmed in Figure S4 showing less 
glycol-group in four PS than in HS using ATR-FTIR, which is widely used to 
analyze the glycoprotein and glycol group 28. The lubrication property of saliva 
in terms of Relief Period demonstrated that Chi-C is able to stabilize the SCF 
and restore the lubrication at macroscale even with saliva from patients 
suffering from Sjögren’s syndrome.  
 
Figure 3. Relief and Relief Period of the S-SCF with patient saliva and healthy saliva in 



















volunteers (a flow rate of 3.36, 1.76, 1.04, 1.02 ml/min) and 4 patients (PS) suffering 
from Sjögren’s syndrome (an aetiology of xerostomia) with a reduced flow rate (0.48, 
0.72, 0.45, 0.98ml/min  ) were collected to transfer this strategy to a real biological 
tissue at macroscale. (a) Healthy S-SCF treated with buffer and (b) patient S-SCF 
treated with buffer. (c) Patient S-SCF and (d) healthy S-SCF treated with Chi-C22.4% 
respectively. (e) Relief induced by patient and healthy S-SCF with buffer and Chi-C22.4% 
treatment. (f) Relief period of patient and healthy S-SCF with buffer and Chi-C22.4% 
treatment. (g) Schematic of Chi-C interaction with salivary mucin and forming a softer 
S-SCF. Error bar represents the standard deviation over 3 independent measurements. 
*Statistically significant (P < 0.05, 2-tailed Student’s t test) differences in relief period 
of healthy S-SCF with buffer and healthy S-SCF with Chi-C22.4% and patient S-SCF with 
Chi-C22.4% with respect to patient S-SCF with buffer. #Significant differences in relief 
period of healthy S-SCF with Chi-C22.4% and patient S-SCF with Chi-C22.4% with respect to 
healthy S-SCF with buffer. Chi-C, chitosan-catechol. 
3.5. Chi-C is antimicrobial, and treated S-SCF decreases dental erosion and 
remains biocompatible  
Here the dental erosion resistance ability of S-SCFs modified with Chi-C as 
shown in Figure 4. The erosion depth of enamel with buffer treated (control) S-
SCF was about 125±24 um, which decreased to 83±19 um with Chi-C7.6% 
treatment, 76±11um with Chi-C14.5% and 70±15 um with Chi-C22.4% treatment. 
Even if there is no significant difference in erosion depths for different 
conjugation densities of Chi-C, Chi-C22.4% treatment S-SCF caused a significant 
drop by 44% in the erosion depth as compared to buffer treatment. The 
erosion prevention could be due to obstruction in citric acid diffusion towards 
the enamel or Ca2+ diffusion outwards. Both these effects are related to the 
compaction of SCF caused by crosslinking (Figure 1) and an increase in the 
thickness of the S-SCF caused by the recruitment of mucin by Chi-C and 
decreasing in the negative charge density within the S-SCF due to the chitosan 
molecule.  
The safety of Chi-C use was tested on L292 and the result is shown in Figure 4c 
and 4d. The overview images on each surface display more cells presented 
over culture time. After 3days of proliferation, the SCF modified with Chi-C22.4% 
even showed a higher metabolic activity, which may be caused by the S-SCF 




cytotoxicity of Chi-C in all conjugation degrees was negligible indicating the 
Chi-C is completely safe for biomedical application.  Catechol conjugation of 
chitosan increased its antimicrobial efficacy on S. mutans UA159, as shown in 
Table S2 and Figure S5. 
 
Figure 4.  Dental erosion prevention and safety of chitosan-catechol (Chi-C). (a) Erosion 
depth under different conditions by optical coherence tomography images. (b) The 
erosion depths were quantified from 3 different samples coated with secondary 
salivary conditioning film (S-SCF) treated with buffer, Chi-C7.6%, Chi-C14.5%, and Chi-C22.4%, 
respectively. (c) Chi-C treatment of salivary conditioning film (SCF) caused higher L929 
proliferation. Fluorescent images of L929 cells were stained with DAPI at days 1, 3, and 
7. (d) Cell metabolic activity measured by XTT. Statistical differences are marked by *P 
< 0.05. 
4. Discussion 
An urgent need exists to develop a new strategy to restore oral lubrication for 
xerostomia patients. Most of the current artificial saliva focuses on optimizing 
the viscosity although it has been shown that there is only little correlation 
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saliva substitutes which overwhelm the oral cavity with exogenous molecules, 
we propose to work along with the highly evolved natural salivary lubrication 
system howsoever aberrant due to disease. Chi-C demonstrates the ability to 
stabilize SCF by the formation of a layered structure with a rigid lower-layer 
due to physical and chemical attraction and followed by formation of the very 
soft top layer (S-SCF) in Figure 1. The ratio between dissipation and frequency 
shift (∆D3/∆f3), was larger than 10
-6 indicating a hydrated, soft SCF formed on 
the QCM-D crystal, which is consistent with the findings of Deepak et al. 20. The 
∆D3/∆f3 for Chi-C treated S-SCF increased irrespective of the conjugation 
degree while no obvious changes found with buffer treatment. Chi-C7.6% with a 
low conjugation degree performed less efficiently in salivary protein 
recruitment indicating that electrostatic attraction does not play a major role 
in salivary protein recruitment when Chi-C was involved. Similar phenomenon 
was found by 12 where higher conjugation degrees of Chi-C resulted in an 
effective association of Chi-C to glycoprotein. The soft top layer is composed of 
mucins recruited from the saliva, as shown by the increase in glycosylation 
(Figure 2b) and layer softness (Figure 1f). This hierarchical structure of S-SCF 
decreased the friction when measured on a nano-scale in Figure 2. However, 
on macro-scale (ex-vivo) with real tissue and Sjögren’s patient saliva, no 
decrease in friction was observed (Relief, Figure 3e) but this nanocomposite 
structured S-SCF generated a longer Relief Period (Figure. 3f). Often it is 
difficult to bridge the gap between macro and micro/nano scale friction 30–32. 
The sliding speeds, applied loads and sliding surfaces during the measurements 
on colloidal probe AFM and tongue-enamel are different yielding different 
results. The significantly lower relief period was observed for PS compare to HS 
after treated with Chi-C22.4% because PS contained either modified or reduced 
glycosylated mucin molecules 25–27 compared to HS, which was confirmed in 
Figure S4 showing less glycol-group in four PS than in HS using ATR-FTIR, which 
is widely used to analyze the glycoprotein and glycol group 28. The lubrication 
property of saliva in terms of Relief Period demonstrated that Chi-C is able to 
stabilize the SCF and restore the lubrication at macroscale even with saliva 




Based on the result from the tongue-enamel friction system, where the total 
amount of fluid is the same but the Relief Period is different, suggests that the 
surface-bound molecules take precedence in lubrication i.e. attracting mucin 
on SCF yield a long-lasting relief period. Treatment with Chi-C gives rise to a 
softer (Figure 1f) and thicker (Figure 1e) top layer which can hold the water for 
a longer period hence the long Relief Period. Similar mechanism was found by 
Singh et al.33 where hyaluronan binding peptides were able to restore the 
lubrication of degraded cartilage. Besides lubrication, The presence of SCFs is 
essential to reduce dental erosion34,35. Thus the resistance of dental erosion by 
the robust S-SCFs enabled by Chi-C also detected in this study. Bovine enamel 
was chosen here because of the high homology of incisors samples between 
bovine and human 36. Our results (Figure 4) show the layered S-SCFs formed 
due to Chi-C treatment decreases dental erosion. Yet another problem of 
xerostomia patients is the high risk on developing oral infections. Chitosan is 
known for its broad-spectrum antibiotic activity, however, this activity is 
limited due to its low solubility at neutral pH. Conjugation with catechol 
enhances chitosan solubility 13 and causes a fourfold reduction in its MIC for S. 
epidermidis 37. We tested the antibacterial activity of Chi-C on the more 
relevant S. mutans UA159. Both MIC (0.5mg/ml) and MBC (1mg/ml) for S. 
mutans are reduced with Chi-C compared to the Chi with a higher MIC 
(1mg/ml) and MBC (2mg/ml) (Table S2, Figure S5). The promising ex vivo 
results obtained for the use of Chi-C indicate that the molecules is a strong 
candidate for human trials. 
In summary, the strategy to work together with the, although impaired but an, 
highly evolved natural lubrication system is promising. A simple mucoadhesive, 
Chi-C, can bind to the SCF and recruit mucins from the saliva by both 
physisorption and chemisorption to form a nanocomposite S-SCF (rigid bottom 
and soft top) to enhance oral lubrication. These structural and compositional 
adjustments in the S-SCF extend the Relief period at macroscale with saliva 











is a strong candidate molecule as an additive to future artificial saliva 
formulations.  
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Materials and Methods 
Chi-C synthesis and characterization. Catechol was conjugated to the amine 
moieties of chitosan by active agent EDC N-(3-dimethylaminopropyl-N-
ethylcarbodiimide hydrochloride 13,38,39. Briefly, Chitosan (50-190 kDa, 3.25 
mmol, Sigma Aldrich, CAS no. 9012-76-4) and hydrocaffeic acid (HCA, 3.25, 
6.49, or 9.75 mmol, Sigma Aldrich, CAS no.1078-61-1) were dissolved in PBS 
(50mL pH=5). EDC (3.25, 6.49 or 9.75 mmol, Sigma Aldrich, CAS no. 25952-53-8) 
and N-hydroxysuccinimide (NHS, 3.25, 6.49 or 9.75 mmol, Sigma Aldrich, CAS 
no. 6066-82-6),were then added to the mixture and stirred at room 
temperature for 12 hours. After extensively dialyzed (Mw cutoff: 3500, USA), 
the product was lyophilized and determined by 1H-NMR (Bruker Avance, 
400MHz, D2O). The degree of catechol substitution determined by Uv-Vis 
spectrum at 280 nm with the standard hydrocaffeic acid curve with different 
concentrations ranging from 0.1mM to 0.9 mM in PBS by linear fitting. After 
obtaining the absorbance of 1 mg/ml Chi-C at 280nm the conjugate degree can 
be calculated. 
Saliva collection and preparation. A standard protocol was followed to collect 
and prepare stimulated (SWS) and reconstituted (RWS) whole saliva as 
described below. SWS from 4 healthy volunteers as well as 4 patients with 
primary Sjögren’s syndrome was collected. The patients with Sjögren’s 
syndrome fulfilled the 2016 ACR-EULAR classification criteria for Sjögren’s 
syndrome. Participants by chewing on parafilm to generate saliva for 15 
minutes. Every minute participants were instructed to expectorate saliva in ice 
cooled flasks. After SWS collection, the SWS was pooled and clarified by 
centrifugation at 10000 rpm at 10°C for 5 minutes. The protease inhibitor 
phenylmethylsulfonyl fluoride was added to stabilize the SWS at final 
concentration of 1 mM. Stimulated whole saliva was collected from 4 healthy 
volunteers with flow rate of 3.36, 1.76, 1.04, 1.02 ml/min. Stimulated whole 
saliva was also collected from 4 patients treated at the Maxillofacial surgery 
department of the University medical Center Groningen (UMCG) with reduced 











X-ray photoelectron spectroscopy.The elemental composition of the S-SCF 
surface was acquired from the X-ray photoelectron spectroscopy (XPS, S-Probe, 
surface science instruments, mountain view, CA, USA). Both low resolution for 
broad scans and high resolution for C1s and O1s peaks were made, where O1s 
peak can be split into two components, the fraction of  O1s peak at 532.7eV (% 
O532.7) from carboxyl groups was used to calculate the amount of oxygen-
related in glycoprotein i.e. mucin amount (%Oglyco)
20. 
%Oglyco=%O532.7 * %Ototal                                  (1) 
Where %O total is the total percentage of oxygen. 
Colloidal probe atomic force microscopy.Friction force and surface topography 
of bare and S-SCF coated QCM crystal were measured using the colloidal probe 
AFM24 (Nanoscope IV Dimension tm 3100) equipped with a Dimension Hybrid 
XYZ SPM scanner head (Veeco, New York, USA). Rectangular, tipless cantilevers 
(length 300±5um, width 35±3um) were glued with a silica-particle (Bangs 
laboratories, Fishers, IN, USA) of 21.83 µm in diameter and calibrated for their 
torsional and normal stiffness by AFM Tune IT v2.5 software42,43. The deflection 
sensitivity (α) of the colloidal probe was recorded at constant compliance with 
bare crystal in buffer to calculate the normal force (Fn) applied using 
Fn=∆Vn ∗ α ∗ Kn                                               (2) 
where ∆Vn is the voltage output from the AFM photodiode due to the normal 
deflection of the colloidal probe. The torsional stiffness and geometrical 
parameters of the probe were used to calculate the friction force ( Ff )
44 
according to 
Ff=(∆VL * Kt) / 2δ * (d + t/2)                         (3) 
where t is the thickness of the cantilever, δ is the torsional detector sensitivity 
of the AFM and ∆VL corresponds to the voltage output from the AFM 
photodiode due to lateral deflection of the probe. Lateral deflection was 
observed at a scanning angle of 90 degrees over a scan area of 30 × 30 µm2 and 
a scanning frequency of 1 Hz. The colloidal probe was incrementally loaded 
and unloaded up to a normal force (Fn) of 40 nN. At each normal force, friction 
loops were recorded to yield the average friction force, Ff.  
Dental erosion and biocompatibility. Dental erosion was tested using an 




(1200 grit grinding paper) and cleaned with deionized water, were partly 
covered with PVC tape exposing an area of approximately 5 × 3 mm in the 
center of the enamel. S-SCF with or without 0.5 mg/ml Chi-C treatment coated 
to the enamel surface (the same procedure as QCMD experiments), finally 
exposed to 50 mM citric acid in PBS for 30 min. The erosion depth then 
analyzed by optical coherence tomography (OCT Ganymade, Thorlabs Inc., 
Munich, Germany). For biocompatibility, a mouse fibroblastic cell line (L929) 
was acquired to co-cultured with S-SCF with Chi-C treatment and cell 
proliferation and metabolic activity measured by XTT23. Briefly, different S-SCF 
with or without Chi-C treatment were coated on the circular glass slide (15mm 
 ) surface that fit for the 24 cell culture plate.  L929 with a concentration of 
5×103 cells/well in a medium of high glucose DMEM (Gibco), 10% FBS (Gibco), 
and 1% penicillin−streptomycin (Sigma) were seeded on the surface for 1d, 3d 
and 7d culture. At each cultured period, XTT for metabolic activity by 
microplate reader recording absorbance at 485 and 690nm and DAPI staining 
for nuclear visualization by confocal laser scanning microscopy (CLSM) were 
measured. 
Evaluation of the antimicrobial activity of Chi-C. The antibacterial activity of 
Chi-C was assessed against S. mutans (UA159). S. mutans were grown on brain 
heart infusion (BHI) agar plates at 37 °C for 24 h. Next an overnight culture (BHI) 
prepared from a single colony was diluted 1:20 in 100ml BHI and incubated at 
37 °C for 16 h. Bacteria were harvested by centrifugation at 5000g after 
washed twice in PBS ( 2.5 mM K2HPO4, 2.5 mM KH2PO4) supplemented with 3% 
v/v BHI to maintain bacterial viability in suspension. Then  suspension was 
sonicated (3 × 10 s, 30 W) in an ice-water bath (Vibra Cell Model 375,Sonics 
and Materials Inc., Danbury, CT, USA). The bacterial concentration was 
calculated by a Bürker-Türk counting chamber .Minimal inhibitory and minimal 
bactericidal concentrations. Bacterial cultures (106 mL−1 in BHI) were dispensed 
into each well of a 96-well microtiter plate with different  Chi-C and Chi 
concentrations, with a step factor dilution of 2 starting from 4mg mL−1, and 
incubated at 37 °C for 24 h. Following incubation, the minimal inhibitory 
concentration (MIC) was taken as the lowest antibiotic concentration that did 











showing no turbidity were plated on BHI agar plates and incubated at 37 °C for 
24 h. The minimal bactericidal concentration (MBC) was taken as the lowest 
concentration at which no colonies were visible on the plate. The experiment 
was performed in triplicate with different bacterial cultures 
Time-kill kinetics. S.mutans (UA159) cultures (1× 106 mL−1 in phosphate buffer 
supplemented with BHI ) were diluted 1 : 10 in Chi-C and control Chi solutions 
in phosphate buffer. After 0, 1, and 2 h, suspensions were serially diluted in 
PBS (10 mM potassium phosphate) and 100 μL aliquots were plated on BHI 
agar plates and incubated for 24 h at 37 °C. The number of colonies formed on 
the plate was then manually counted. 
Results 
Preparation and characterization of Chi-C 
Figure S1 shows the synthesis and characterization of three conjugates of Chi-C 
with three equivalent proportions (1:1, 1:2, 1:3) between chitosan and 
hydrocaffeic acid (figure S1a). The conjugate were analyzed by H-NMR spectra 
and UV-Vis spectrometry as shown in Figure S1b-c. The NMR spectra in Figure 
1b, where multiplets observed between δ = 6.5 ppm and δ = 7.0 ppm are 
associated with protons of the catechol12,13; the region around 2ppm 
corresponds to protons from acetyl, demonstrating the Chi-C conjugation was 
successful. The adsorption band at 280 nm of Uv-Vis spectrum in Figure S1c, 
the characteristic band of the aromatic ring, confirms the conjugation 
successful. The conjugation degree was calculated using the standard curve of 
hydrocaffeic acid in Figure S2. After obtaining the absorbance of 1 mg/ml Chi-C 
at 280nm in FigureS1c the conjugate degree was calculated as 7.6% (Chi-C7.6%), 
14.5% (Chi-C14.5%) and 22.4% (Chi-C22.4%). These conjugations degrees cover the 
whole range which is commonly used in literature 12,39, thus we used them to 





Figure S1. Chi-C synthesis and characterization. (a) is the synthesis route and the final 
structure of Chi-C. (b) and (c) are
1
 H-NMR spectra and Uv-vis spectra of Chi-C 
respectively. 
 
Figure S2. Uv-Vis spectra of hydrocaffeic acid solution at A280 with different 
concentration from 0.1mM to 0.9mM and the standard curve was calculated by linear 
fitting. Once we get the absorbance of 1 mg/ml Chi-C at 280nm the conjugate degree 














Figure S3 XPS analysis elemental composition of S-SCF treated with (a) buffer; (b) Chi-
C7.6%; (c) Chi-C14.5% and (d) Chi-C22.4% and the decomposition of C1S and O1S. C1s spectra 
of each surface could be deconvoluted into four different curves: C−(C,H), C−N/C−O, 
O−C−O, O−C=O and their percentages for S-SCF with PBS or S-SCF with various kind of 
Chi-C is different, suggesting different protein were detected from surface. As for the 
O1s spectra, the relative contents of glycoprotein
20
 could be calculated by integral of 
O1s at 532.7ev.  
 
FigureS4. Typical FTIR adsorption bands for four patient saliva and healthy saliva 
measured in ATR-FTIR. 20 ul of each saliva (healthy saliva and patient saliva) was 
measured on a ATR-FTIR (Cary 600 series FTIR spectrometer, Agilent Technologies, 
Santa Clara, USA). Clearly visible glycol group peaks is from 950 to 1200cm
-1
 and the 
absorbance band from 1600 and 1700cm
-1
 related to the amide I peaks indicative of 




. The higher 
C1s
O1s




absorbance and peak area of glycol group from all four healthy saliva were observed 
(zoomed in with the insertion ) compared to the patient saliva, indicating less 
glycosylation of mucin in patient salvia. 
 
Figure S5. Efficacy of Chi-C kill S. mutans. Table 1 the MIC and MBC of Chitosan and 
Chi-C with various conjugate degree. 
Table S1 Elemental composition of S-SCF treated with buffer, Chi-C7.6%, Chi-C14.5%, and 
Chi-C22.4%. ± indicates standard deviation over three measurements. 













C 51.9±1.65 56.63±2.4 56.68±1.35 54.8±3.5 









 5.39±2.25 7.04±2.6 9.35±1.3 9.88±1.6 
K 8.72±3.8 7.01±2.8 5±0.56 8.5±1.4 
Cl 7.87±3.7 6.08±1.49 5±0.99 7.8±0.35 
P 8.95±0.92 4.64±0.19 5.2±1.37 3.45±1.2 














Table S2. MIC and MBC of  Chi-C for oral bacterial S. mutans(UA159) 
 
MIC (mg/ml) MBC (mg/ml) 
Chitosan 1 2 
Chi-C7.6% 0.5 1 
Chi-C14.5% 0.5 1 
Chi-C22.4% 0.5 1 
 
